We're trying something with Roche here, where we think that we are currently in Wave (5), having recently completed Wave (4). This assessment is better visualized on the daily chart. Hence, we should maintain the 61.8% level for this Wave 4. Anything below would statistically be too low, while above, we aim at least to revisit the old high, up to an Wave 5...
Hi, 1PERCENT here. Roche Holding, a Swiss multinational biopharma company. It is like the Apple of biopharma. There were only 3 pull backs greater than 30% in the history of the stock. 2002 ~ 2003: -45.33% 2006 ~ 2011: -52.40% 2014 ~ 2018: -30.24% 2022 ~ present: -44.89% It is at the support zone that initiated the +95% move up from 2018 to 2022, and also is...
Trend started in 2012 held during the week. If the price accumulates at the current level and we breakout to the upside, I will watch the marked zones of interest and see how the price reacts. If we breakout to the down side, I will look for interesting price levels and keep an eye on the trend established in 2003. As of now I am long.
Hello ladies and gentlemen, according to my stock chart analysis, there is a high probability of a decline toward the $303.50 level in the next few days!
PIRS Pieris Pharmaceuticals has collaboration agreements with AstraZeneca, Boston Pharmaceuticals, Servier, Seagen and Genentech, part of Roche. AZN AstraZeneca 70Mil upfront payment and 5.4Bil potential milestone payments Boston Pharmaceuticals 10Mil upfront payment and 353Mil potential milestone payments Genentech member of RHHBY Roche Group 20Mil upfront...
Roche making higher lows inside a descending broadening wedgem, while showing signs of accumulation with a sell wall at 326.85$. The bullish engulfing candles on Jan 11 and the Marubozu on Feb 4 show that the demand for this asset is high at the previous Peak back in December 2014. The fact that there is also MACD hidden bullish divergence on the daily and the...
2W 50 MA should be in the pocket. Ready to continue higher. BIO
Vaccibody announces the closing of the worldwide license and collaboration agreement with Genentech All antitrust contingencies required to close the agreement with Genentech, regarding the development of individualized neoantigen cancer vaccines, have been satisfied Oslo, Norway, November 06, 2020 – Vaccibody AS, a clinical-stage biopharmaceutical company...
The market is bullish and the idea is to invest in the Market direction. Fundamental Analysis Info: Britain is in talks with Swiss drugmaker Roche Holding AG (ROG.S) to buy an accurate COVID-19 antibody test, following the lead of the European Union and United States, which had already given preliminary approval to the tests.
Dates in the future with the highest probability for price direction reversals
Dates in the future with the highest probability for price direction reversals
Dates in the future with the highest probability for price direction reversals
RHHBY has seen two previous bump and run formations and is looking for a continuation with a third bump and run, indicated by the green fractal. These bumps form above the natural trend and a bearish reversal slowly follows. Again I recommend ‘Encyclopedia of Chart patterns’ By TN Bulkowski for anyone interested in learning some patterns.
Regenerative medicine company developing novel placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic...
I have been looking at stocks a little bit on the side, once in a while, for a long time. Now I think I have to really get into it, the way I do things (the RIGHT way is the name I think), I just look for good opportunities, I don't focus on just a few and try to force money out of the market (lol). And with currencies, well... This: Whereas stocks are...
On a large time frame. Roche is on a steady uptrend. Currently it is at the support which brings in very good opportunity for a buy in for Long term holdings (20years)
The has been absolutely no fundamental change to this bio company that has multiple big pharma partners. Yet due to the overall biotech downturn NASDAQ:PIRS was hit pretty hard. This presents a true 10 bagger opportunity , and Im not even remotely stretching the truth. The technicals show you why right now is the PERFECT time to buy. A little due diligence will...